Intersect - Metastatic Disease Pt. 2

Rose Higgins, chief executive officer at HealthMyne, sits down with Sam to discuss the role radiomics is playing in cancer care. Our biology-guided radiotherapy will generate a plethora of new data that will one day become part of the data fabric to help us understand what is happening at both the molecular and biological level. This podcast dives into how radiomics can provide insights to better inform treatment decisions and what the future may hold.

RefleXion's Chief Business Officer, Thorsten Melcher Ph.D., and Chris Behrenbruch Ph.D, founder and CEO of Telix Pharmaceuticals, explore how holistic treatment strategies for metastatic cancer patients interact with the world of commerce. What is the role of radiopharmacueticals in the radiotherapy delivery? What influence does the design of clinical trials have on market authorization? Why would a company deliberately integrate with an existing therapy rather than replace it? Find out in this forward-looking discussion.Speakers:Thorsten Melcher Ph.D. - CBO, RefleXionChris Behrenbruch Ph.D, - Founder and CEO, Telix PharmaceuticalsFor more information, please visit https://reflexion.com

Thorsten Melcher Ph.D., CBO at RefleXion, and Dr. Giovanni Selvaggi, CEO and CMO at Xcovery, discuss advances in two key areas that could mean a longer life for more Stage 4 patients. The watchwords are customization and personalization. The finding that the customized pairing of two therapies, used in combination, versus in a sequence, creates a synergistic effect, is coupled with the realization every patient's cancer is personalized to their unique system. Developing a plan that includes a patient assessment, multiple treatment options, and how best to combine them, is a promising new direction.Speakers:Thorsten Melcher Ph.D. - CBO, RefleXionGiovanni Selvaggi, M.D. - CEO & CMO, XcoveryFor more information, please visit https://reflexion.com

Dr. Arya Amini, faculty radiation oncologist at City of Hope Cancer Center, joins Sean to discuss the promise and complexity of envelope-pushing therapies and current state of clinical research. Dr. Amini's fascination with cancer took hold in high school, continued through medical school, and ultimately has brought him to the field of radiation oncology – allowing him to focus on both patients and research. Hear how the industry has shifted from IMRT to SBRT and now a focus on both local and systemic therapies to treat metastatic disease. This forward-thinking conversation covers a lot of ground and you don't want to miss it.Speakers:Arya Amini, M.D. - Assistant Clinical Professor and Chief of Thoracic Radiotherapy, Department of Radiation Oncology for City of Hope Comprehensive Cancer CenterSean Shirvani, M.D. - Chief Medical Officer, RefleXionFor more information, please visit https://reflexion.com

Sean is joined by Dr. George Simon, Executive Director of Moffitt Cancer Center-AdventHealth joint Clinical Research Unit, to identify key crossroads in the treatment landscape for metastatic cancer patients. If the distinctions among systemic, local, and immunotherapies are a bit baffling to you they won't be for long. Dr. Simon details these and other approaches such as checkpoint inhibitors, available in the just the last five years or so. The pace of change is exhilarating for physicians and patients. Though there is still much to learn, there is also much to celebrate.Speakers:George Simon, M.D. - Executive Medical Director and Department Chair, Moffitt Cancer Center-AdventHealth joint Clinical Research UnitSean Shirvani, M.D. - Chief Medical Officer, RefleXionFor more information, please visit https://reflexion.com

Sam and Sean examine the history of cancer and how imprecise, untargeted treatments were ushered out in favor of cellular and immunotherapies which bring fundamentally different approaches to the fight. The story of how 100 years of accepted knowledge was upended by an experiment with mice, radiation, and their immune systems may surprise you. Even the categorization of cancers by their origin...breast cancer, lung cancer...is giving way. The conversation culminates with a newcomer in the ever-evolving history of changing outcomes for metastatic cancer patients: Biology-guided radiotherapy (BgRT).Speakers:Sam Mazin, PhD - Founder and CTO, RefleXionSean Shirvani, M.D. - Chief Medical Officer, RefleXionFor more information, please visit https://reflexion.com

Dr. Sean Shirvani, SVP of Clinical and Medical Affairs for Reflexion, shares his thinking about the word no one wants to hear: Metastasized. Worldwide, metastatic disease is responsible for 9 of 10 cancer deaths. This is grim on a global scale. But there is hope. Every year brings new treatment discoveries, and the momentum is building. In this series, Dr. Shirvani and his guests explore The Future of Cancer.Speakers:Sean Shirvani, M.D. - Chief Medical Officer, RefleXionFor more information, please visit https://reflexion.com

What if cancer could communicate directly with a machine? This is the question that started it all for co-founder and CTO, Sam Mazin while he was a postdoc at Stanford. He understood how radiology systems worked, and then set out to learn about radiation oncology. As he began to think about the two processes, a new treatment modality was born — using x-rays to see disease, and treat cancer, simultaneously. Tune in to find out what happened next — including the biggest challenge: raising $10,000,000. It’s all part of the story of how RefleXion was born.Speakers:Sam Mazin, PhD - Founder and CTO, RefleXionTodd Powell - President and CEO, RefleXionFor more information, please visit https://reflexion.com

Have you ever heard the expression “an overnight success takes 10 years”? Well, that’s where we are. Actually, year 11. Though it’s been a long road, that didn’t dampen our determination. This year we sold our first X1 machines, realized the vision of our Clinician Learning Center, and gained support from some very influential healthcare organizations, among many other milestones. Listen to the details of how things shaped up for RefleXion in 2020. Then, tune in to our next episode for a lively discussion with our co-founder and CTO, Sam Mazin.Speakers:Todd Powell - President and CEO, RefleXionFor more information, please visit https://reflexion.com

RefleXion is a bio-targeting company. If you haven’t heard of that before, it’s not surprising. We’re different. Our biology-guided radiation therapy turns cancer on itself. What do we mean by that? RefleXion’s X1 machine literally causes cancer to reveal itself at the time of treatment. Intrigued? Have a listen and discover more from our President and CEO, Todd Powell, as he discusses this breakthrough technology and the opportunities that lie ahead. Then, check out our next podcast to learn about this year’s break through milestones.Speakers:Todd Powell - President and CEO, RefleXionFor more information, please visit https://reflexion.com